Solutions

Online Inquiry

Global Services. (Creative Biolabs Authorized)

CAR-T Cell In Vivo Anti-Tumor Activity Enhancement Service

Online Inquiry

Background Service What we can offer Workflow HighlightsPublished Data FAQs Customer Reviews Contact

Creative Biolabs offers a comprehensive CAR-T Cell In Vivo Anti-Tumor Activity Enhancement Service designed to address limited persistence, cytokine-related toxicity, and insufficient tumor infiltration in solid malignancies. Our platform enhances CAR-T therapeutic performance through structural signalosome optimization, including innovative CD3 subunit reconstitution, combined with advanced locoregional delivery strategies to improve in vivo functionality. By integrating metabolic fitness profiling, high-throughput screening, and TME-adaptive tumor models, we systematically optimize CAR-T constructs for durability and efficacy.

Introduction

CAR-T therapy often encounters hurdles in solid tumors due to rapid exhaustion and systemic toxicity. Substituting conventional CD3ε modules for CD3ζ has been shown to reduce cytokine release and tonic signals while enhancing memory differentiation. Furthermore, studies demonstrate that locoregional delivery effectively bypasses physical barriers such as the blood-brain barrier in glioblastoma. These structural and delivery refinements are essential for enhancing in vivo activity and ensuring long-term disease remission in complex tumor microenvironments.

Service

Creative Biolabs delivers precise engineering solutions to overcome biological barriers in CAR-T therapy. We provide optimized intracellular modules that reduce tonic signaling, directly preventing premature T-cell exhaustion. Our deliverables include remodeled metabolic profiles enabling cells to thrive in hypoxic tumor environments and optimized delivery routes that maximize infiltration. By moving from unstable prototypes to lead candidates with verified in vivo potency and manageable safety profiles, we ensure your project meets rigorous clinical-readiness standards.

Discover How We Can Help - Request a Consultation.

Technical Capabilities

We offer a suite of mainstream technology platforms tailored for functional enhancement:

Intracellular Signalosome Reconstitution: Optimized CD3 subunit swapping to tune activation thresholds.
Metabolic Fitness Engineering: Gene editing to improve T-cell survival in nutrient-deprived TMEs.
Locoregional Delivery Optimization: Validated protocols for peritumoral, intraperitoneal, and intracranial administration.
Logic-Gated Circuit Design: Implementation of AND/OR gates to increase tumor specificity and safety.
3D Infiltration Assays: High-throughput screening using tumor spheroids to predict in vivo migration capabilities.

Workflow

Required Starting Materials:

scFv sequence or baseline CAR plasmid maps.

Target antigen expression profile of your specific tumor cell lines.

Desired therapeutic target profile.

Workflow of CAR-T Cell In Vivo Anti-Tumor Activity Enhancement. (Creative Biolabs Original)

Final Deliverables:

Optimized CAR-T candidate plasmids and verified stable cell lines.

Comprehensive data reports including in vivo efficacy, persistence kinetics, and histopathological analysis.

Detailed cytokine toxicity profiles and metabolic fitness datasets.

Primary Benefits

Combinatorial Approaches: Support combination with checkpoint inhibitors, cytokine modulation, or tumor microenvironment remodeling.
Data-Driven Insights: Integration of pharmacokinetics, tumor burden monitoring, and immune profiling for actionable results.
Customizable Solutions: Tailored to your CAR construct, tumor type, and experimental objectives.

Published Data

This study explores a novel way to improve CAR-T cell therapy by redesigning its core signaling component. Instead of the conventional domain, they built CARs using alternative signaling modules from different CD3 proteins. These new designs, particularly one based on the CD3ε chain, improved safety by reducing excessive cytokine release and enhancing cell persistence, without compromising anti-tumor activity.

Fig.1 A CAR bearing a novel intracellular module potentiates T cell-mediated antitumor effects. (OA Literature) Fig.1 CARs equipped with novel intracellular domains augment the antitumor efficacy of T cells.¹

FAQs

Q1: What types of CAR-T cells can be tested?

A1: We accommodate various CAR-T constructs, including second- and third-generation CARs, with autologous or allogeneic T cells.

Q2: What in vivo models are available?

A2: Mouse models include syngeneic, xenograft, and humanized mice, with tumor types ranging from solid tumors to hematological malignancies.

Q3: Can you evaluate combination therapies?

A3: Yes, we support the evaluation of CAR-T cells with checkpoint inhibitors, cytokines, chemotherapies, or other immunomodulators.

Q4: How is CAR-T efficacy measured?

A4: Through tumor volume tracking, bioluminescence imaging, flow cytometry for CAR-T persistence, and cytokine profiling.

Customer Reviews

"The in vivo CAR-T studies provided by Creative Biolabs were truly outstanding. The team guided us through the entire process, from designing the study to optimizing our CAR-T cells for enhanced tumor infiltration and long-term persistence. The data we received was not only comprehensive but also highly reproducible, allowing us to make critical decisions for our preclinical program. Their attention to detail and scientific expertise exceeded our expectations at every stage."

— P***K M.

"Working with Creative Biolabs was a game-changer for our CAR-T research. They provided a fully integrated service that included in vivo efficacy testing, immune profiling, and pharmacokinetic analysis. The team's responsiveness and ability to tailor the study design specifically for our CAR construct made the process seamless."

— D***S E.

Partner with Us

Creative Biolabs offers a comprehensive suite of services designed to enhance the in vivo anti-tumor activity of CAR-T cells, integrating scientific rigor with practical solutions to accelerate translational research. Our offerings cover the full spectrum of in vivo CAR-T evaluation, including optimized xenograft, syngeneic, and humanized mouse models, immune cell interaction analysis, combination therapy assessment, and detailed functional profiling of CAR-T persistence, infiltration, and cytotoxicity.

We encourage researchers, biotech innovators, and academic teams to reach out to Creative Biolabs to discuss how our in vivo CAR-T enhancement services can be applied to their projects. From study design to execution and detailed data reporting, we provide guidance and support at every stage, helping your CAR-T programs achieve optimal efficacy and translational relevance.

Reference

Wang, Pengju et al. "Chimeric antigen receptor with novel intracellular modules improves antitumor performance of T cells." Signal transduction and targeted therapy vol. 10,1 20. 15 Jan. 2025. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.1038/s41392-024-02096-5

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.